Keyword: Relay Therapeutics
As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.
Relay's $400 million series C round came just two years after its official launch and relatively modest $57 million A round.
Private biotechs raised a record-breaking $16.8 billion in 2018, blowing past the record $12.1 billion set the previous year. Here are the top 10 fundraising rounds—which broke some records themselves and together illustrate what's hot out there in the field.
Relay Therapeutics reeled in a $400 million round to boost its platform technology and discovery efforts, build its pipeline and get into the clinic.
Xenotransplantation firm eGenesis hires new R&D head; Relay adds execs to chemistry, R&D; and Navidea brings on new CMO focused on imaging.
Relay Therapeutics brought on Verastem’s Mahesh Padval and Eli Lilly’s Mary Mader as it begins to transition to a development-stage biotech.
Celgene COO Scott Smith resigns, ex-Kite leaders Belldegrun and Chang form new CAR-T shop, GSK Dermatology exec jumps to Dermavant.
Relay Therapeutics has bumped up its cash with a strong second funding round as it eyes clinical work on its next-gen cancer drug development.
Pfizer creates COO role, Bayer replaces consumer health chief, Turnstone poaches Bristol-Myers executive as new R&D head and more.
Because proteins move constantly inside cells, Relay’s A-list founders and investor Third Rock Ventures think showing motion will reveal new ways to treat diseases. The first step is to go after the many frequently mutated oncogenes the industry is yet to drug.